Please register or login to view the chart


Sulfasalazine is a synthetic salicylic acid derivative with an affinity for connective tissue containing 
elastin and formulated as a prodrug , antiinflammatory Sulfasalaine acts locally in the intestine 
through its active metabolite , sulfamide 5-aminosalicylic acid and salicylic acid , by a mechanism
 that is not clear ( Pubchem )

Salazopyrin En-Tabs 500 mg tablets also comes with Enteric coating to reduce GI SEs Typical regimen may start with 500 mg / day ↑ ed at intervals of 1 week by one 500 mg tablet a day to a max of 2-3 gm in divided doses

Ulcerative Colitis -induction and maintenance of remission Crohn’s disease – treatment Rheumatoid arthritis Sero negative spondylo-arthopathy ( including psoriatic arthritis and Psoriasis ) Can be used as monotherapy or in combination

Is a prodrug Structurally related to both salicylates ( for eg aspirin ) and sulphonamides Split by bacterial in colon into Sulfapyridine ( SP ) & Mesalazine MP ) Precise mechanism of action not know Local actions of mesalamine in colon – likely reason for effectiveness in inflammatory bowel dis RA- may be related to anti-inflammatory and immunomodulatory properties In rheumatoid arthritis a disease-modifying effect is seen in 1-3 months ( reduction in inflammatory markers ) Renal/Faecal- primary excretion routes

Adverse effects

Adverse reactions are possible to either Suphonamide or Salicylate Most commonly encountered are nausea , headache , rash , loss of appetite and raised temperature

Few other points
 May discolour contact lenses ( yellow/ orange ) Can cause a fall in sperm count- leading to a reversible temporary decrease in male fertility Pregnancy- can be used not teratogenic Breast feeding – small amounts in milk ( risk neonatal haemolysis ) Patients with known ANA→ can induce lupus like illness G6PD ( glucose -6-phosphate dehydrogenase ) risk haemolytic anaemia

Digoxin- reduced absorption Hypoglycaemia risk ( if on hypoglycaemic agents ) Increased GI adverse effects -particularly nausea if used with Methotrexate Azathioprine / Mercaptopurine →bone marrow suppression and leucopenia

Monitoring- FBC or CBC Fortnightly for the 1st 3 months Monthly for 2nd 3 months 3 monthly or as clinically indicated after that WBC < 3.5 x 109 / L Neutrophils < 2 x 109 / L
( threshold may vary locally from
1.5 to 2 check with local team ) Platelets < 150 x 109 / L

 MCV > 105 fL 
○ check Vit B12 and TSH
○ If abnormal treat underlying abnormality
○ If normal discuss with specialist team Withhold treatment until discussed with specialist team

LFT Fortnightly for the 1st 3 months Monthly for 2nd 3 months 3 monthly or as clinically indicated after that AST , ALT → twice upper limit of normal Withold treatment until discussed with specialist team

us and Es Renal function test Urinalysis Monthly for 1st 3 months As clinically indicated after that Excreted in urine and accumlation is associated with ↑risk of toxicity 

Check for presence of rash or oral ulceration
( each visit )
 Nausea / dizziness / headache

 Abnormal bruising , pallor , severe sore throat , fever malaise

 Unexplained acute widespread rash

 Oral ulceration



Versus arthritis on sulfasalazine – a well written 8 page leaflet

Australian Rheumatology Association

Medline Plus on Sulfasalazine

Medicine compendium on sulfasalazine

American College of Rheumatology on Sulfasalazine

Alberta rheumatology -concise PIL

A balanced well written informative page for patients from Health Navigator New Zealand



A review article on DMARD monitoring Rigby WFC, Lampl K, Low JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDsInt J Rheumatol. 2017;2017:9614241. doi:10.1155/2017/9614241

Another article on DMARD monitoring from BPAC NZ

FDA on sulfasalazine a 21-page document

Use of sulfasalazine in dermatology from DermNet Nz

A complete resource on sulfasalazine from PDR Net

Drugbank database on sulfasalazine

References ;

  1.  BSR/ BHPR guideline for disease-modifying anti-rheumatic drug ( DMARD ) therapy in consultation with the British Association of Dermatologists K Chakravarty et al Rhematology 2008 ; 1 of 16
  2. Gwent Shared Care Protocol Sulfasalazine for Rheumatoid Arthritis ABHB
  3. Drugbank accessed via
  4. CKS NKS accessed via!scenario:11
  5. Shropshire Clinical Commissioning Group
  6. Wirral University Teaching Hospitals










Related Charts:

Add Your Comments

Your email address will not be published.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

A4 Medicine  - Search Less and Learn More

Welcome to the A4 medicine community where we are constantly working to provide exceptional educational material to primary health care professionals. Subscribe to our website for complete access to our A4 Charts. They are aesthetically designed charts that contain 300 (plus and adding) common and complex medical conditions with the all information required for primary care in one single page that can help you in consultation/practice and exam.

Additionally, you will get complete access for our Learn From Experts : A4 Webinar Series in which domain experts share the video explainer presentation on one medical condition in one hour for the primary care. And you will also get a hefty discount on our publications and upcoming digital products.

We are giving a lifetime flat 30% discount to our first thousand users, discount code already applied to checkout.